ArticleBiomedicines2022
Impact of COVID-19 and Antibiotic Treatments on Gut Microbiome: A Role for
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Gut microbial profiles of COVID-19 patients in Uganda.African health sciences · 2026Article
- Surgical Site Infections and Antimicrobial Resistance: Six Years of Data from a Western Romanian Hospital.Medicina (Kaunas, Lithuania) · 2026Article
- Metaproteomics reveals age-specific alterations of gut microbiome in hamsters with SARS-CoV-2 infection.Gut microbes · 2025Article
- Gut Microbiota and COVID-19: Unraveling the Gut-Lung Axis and Immunomodulatory Therapies.ACS infectious diseases · 2025Review
- Impact of Vitamins, Antibiotics, Probiotics, and History of COVID-19 on the Gut Microbiome in Ulcerative Colitis Patients: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.Computational and structural biotechnology journal · 2025Review
- Large-scale genetic correlation studies explore the causal relationship and potential mechanism between gut microbiota and COVID-19-associated risks.BMC microbiology · 2024Article
- Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota.Biomedicines · 2024Article
- Gut Microbiome Disruption Following SARS-CoV-2: A Review.Microorganisms · 2024Review
- Gut Microbiome Composition and Dynamics in Hospitalized COVID-19 Patients and Patients with Post-Acute COVID-19 Syndrome.International journal of molecular sciences · 2024Article
- Article
- Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Promising Markers of Inflammatory and Gut Dysbiosis in Patients with Post-COVID-19 Syndrome.Journal of personalized medicine · 2023Article
- T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens.International journal of molecular sciences · 2023Article
- Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method.Frontiers in cellular and infection microbiology · 2023Article
- Gut microbiota composition is associated with disease severity and host immune responses in COVID-19.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveSeveral studies showed the substantial use of antibiotics and increased risk of antimicrobial resistant infections in patients with COVID-19. The impact of COVID-19-related treatments and antibiotics on gut dysbiosis has not been clarified.
designThe prospective cohort study included hospitalized COVID-19 patients (April-December 2020). The gut microbiome composition was analysed by 16S sequencing. The gut diversity and changes in opportunistic bacteria (OBs) or symbionts were analysed according to clinical parameters, laboratory markers of disease progression, type of non-antibiotic COVID-19 treatments (NACT) and type, WHO AWaRe group, and duration of antibiotic therapy (AT).
resultsA total of 82 patients (mean age 66 ± 13 years, 70% males) were enrolled. The relative abundance of
conclusionMicrobiome diversity is affected by COVID-19 severity. In this context, antibiotic treatment may shift the gut microbiome composition towards OBs, particularly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.